Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1978 1
1979 4
1981 1
1983 1
1984 4
1985 2
1986 1
1987 4
1988 1
1989 4
1990 6
1991 8
1992 5
1993 5
1994 13
1995 9
1996 8
1997 9
1998 9
1999 10
2000 14
2001 17
2002 11
2003 21
2004 15
2005 10
2006 13
2007 25
2008 28
2009 32
2010 22
2011 35
2012 47
2013 49
2014 41
2015 45
2016 41
2017 45
2018 60
2019 64
2020 77
2021 71
2022 85
2023 72
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

925 results

Results by year

Filters applied: . Clear all
Page 1
Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Terrault N, et al. Gastroenterology. 2018 Sep;155(3):705-718. doi: 10.1053/j.gastro.2018.05.025. Epub 2018 May 17. Gastroenterology. 2018. PMID: 29778606 Free article. Clinical Trial.
BACKGROUND & AIMS: Patients with thrombocytopenia and chronic liver disease (CLD) may require platelet transfusions before scheduled procedures to decrease risk of bleeding. ...METHODS: In the ADAPT-1 and ADAPT-2 studies, adults with thrombocytopenia and …
BACKGROUND & AIMS: Patients with thrombocytopenia and chronic liver disease (CLD) may require platelet transfusions before …
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Kuter DJ, et al. N Engl J Med. 2022 Apr 14;386(15):1421-1431. doi: 10.1056/NEJMoa2110297. N Engl J Med. 2022. PMID: 35417637 Clinical Trial.
RESULTS: Sixty patients were enrolled. At baseline, the median platelet count was 1510(3) per cubic millimeter, the median duration of disease was 6.3 years, and patients had received a median of four different immune thrombocytopenia therapies previou …
RESULTS: Sixty patients were enrolled. At baseline, the median platelet count was 1510(3) per cubic millimeter, the med …
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Legendre CM, et al. N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981. N Engl J Med. 2013. PMID: 23738544 Free article. Clinical Trial.
The primary end points included a change in the platelet count (in trial 1) and thrombotic microangiopathy event-free status (no decrease in the platelet count of >25%, no plasma exchange or infusion, and no initiation of dialysis) (in trial 2). RES …
The primary end points included a change in the platelet count (in trial 1) and thrombotic microangiopathy event-free status ( …
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J, Arnold DM, Grossbard E, Mayer J, Treliński J, Homenda W, Hellmann A, Windyga J, Sivcheva L, Khalafallah AA, Zaja F, Cooper N, Markovtsov V, Zayed H, Duliege AM. Bussel J, et al. Am J Hematol. 2018 Jul;93(7):921-930. doi: 10.1002/ajh.25125. Epub 2018 May 15. Am J Hematol. 2018. PMID: 29696684 Free PMC article. Clinical Trial.
The primary endpoint was stable response (platelets 50 000/muL at 4 of 6 biweekly visits, weeks 14-24, without rescue therapy). Baseline median platelet count was 16 000/muL; median duration of ITP was 8.5 years. Stable responses occurred in 18% of patients o …
The primary endpoint was stable response (platelets 50 000/muL at 4 of 6 biweekly visits, weeks 14-24, without rescue therapy). Baseline …
Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study.
Guillet S, Crickx E, Azzaoui I, Chappert P, Boutin E, Viallard JF, Rivière E, Gobert D, Galicier L, Malphettes M, Cheze S, Lefrere F, Audia S, Bonnotte B, Lambotte O, Noel N, Fain O, Moulis G, Hamidou M, Gerfaud-Valentin M, Marolleau JP, Terriou L, Martis N, Morin AS, Perlat A, Le Gallou T, Roy-Peaud F, Robbins A, Lega JC, Puyade M, Comont T, Limal N, Languille L, Zarrour A, Luka M, Menager M, Belmondo T, Hue S, Canoui-Poitrine F, Michel M, Godeau B, Mahévas M. Guillet S, et al. Blood. 2023 Jun 8;141(23):2867-2877. doi: 10.1182/blood.2022018665. Blood. 2023. PMID: 36893453
The primary end point was the proportion of patients achieving SROT (platelet count >30 109/L and no bleeding) at week 24 (W24) with no other ITP-specific medications. Secondary end points included the proportion of sustained CR off-treatment (SCROT, platelet …
The primary end point was the proportion of patients achieving SROT (platelet count >30 109/L and no bleeding) at week 24 ( …
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A; ADVANCE Investigator Study Group. Broome CM, et al. Lancet. 2023 Nov 4;402(10413):1648-1659. doi: 10.1016/S0140-6736(23)01460-5. Epub 2023 Sep 28. Lancet. 2023. PMID: 37778358 Clinical Trial.
Patients were randomly assigned 2:1 to receive either efgartigimod (10 mg/kg) or placebo intravenously for the first 4 weeks, after which the dosing schedule could be altered to once per week or every other week depending on the patients' platelet count. The primary …
Patients were randomly assigned 2:1 to receive either efgartigimod (10 mg/kg) or placebo intravenously for the first 4 weeks, after which th …
Heparin-induced thrombocytopenia.
Krzych ŁJ, Nowacka E, Knapik P. Krzych ŁJ, et al. Anaesthesiol Intensive Ther. 2015;47(1):63-76. doi: 10.5603/AIT.2015.0006. Anaesthesiol Intensive Ther. 2015. PMID: 25751293 Free article. Review.
Antithrombotic therapy with "new" anticoagulants should be carried out at least until platelet counts return to the baseline values; the recommended duration of therapy is 4 weeks in patients with isolated thrombocytopenia or 4 months in those with thrombotic …
Antithrombotic therapy with "new" anticoagulants should be carried out at least until platelet counts return to the baseline v …
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Cheng G, et al. Lancet. 2011 Jan 29;377(9763):393-402. doi: 10.1016/S0140-6736(10)60959-2. Epub 2010 Aug 23. Lancet. 2011. PMID: 20739054 Clinical Trial.
METHODS: We undertook a phase 3, double-blind, placebo-controlled study in adults with previously treated immune thrombocytopenia of more than 6 months' duration who had baseline platelet counts lower than 30,000 per muL. ...Randomisation was done centrally w …
METHODS: We undertook a phase 3, double-blind, placebo-controlled study in adults with previously treated immune thrombocytopenia of …
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Wong RSM, et al. Blood. 2017 Dec 7;130(23):2527-2536. doi: 10.1182/blood-2017-04-748707. Epub 2017 Oct 17. Blood. 2017. PMID: 29042367 Free article. Clinical Trial.
In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding. ...Overall, 259 patients (85.8%) achieved a response (platelet count 50 10( …
In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with chronic/persistent immune thrombocytopenia (ITP) incr …
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Newland AC, Sánchez-González B, Rejtő L, Egyed M, Romanyuk N, Godar M, Verschueren K, Gandini D, Ulrichts P, Beauchamp J, Dreier T, Ward ES, Michel M, Liebman HA, de Haard H, Leupin N, Kuter DJ. Newland AC, et al. Am J Hematol. 2020 Feb;95(2):178-187. doi: 10.1002/ajh.25680. Epub 2019 Dec 10. Am J Hematol. 2020. PMID: 31821591 Free PMC article. Clinical Trial.
Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder, characterized by a low platelet count (<100 10(9) /L) in the absence of other causes associated with thrombocytopenia. ...Efgartigimod induced a rapid reduction of to …
Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder, characterized by a low platelet count …
925 results